Alexander Dobrovic
Overview
Explore the profile of Alexander Dobrovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
177
Citations
5792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fink J, Jaradi B, Stone N, Sanker B, Zhang F, Dobrovic A, et al.
J Mol Diagn
. 2024 Dec;
27(2):139-153.
PMID: 39675559
Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors represent a significant advancement in the treatment of epithelial ovarian cancer, triple-negative breast cancer, pancreatic cancer, and castrate-resistant prostate cancer, and they are poised...
2.
Chung W, Wong K, Ravindranayagam N, Tang L, Grace J, Wong D, et al.
World J Transplant
. 2024 Sep;
14(3):94914.
PMID: 39295976
Background: Liver transplantation (LT) is a potentially curative therapy for patients with hepatocellular carcinoma (HCC). HCC-recurrence following LT is associated with reduced survival. There is increasing interest in chemoprophylaxis to...
3.
Nesic K, Krais J, Wang Y, Vandenberg C, Patel P, Cai K, et al.
Mol Cancer
. 2024 Aug;
23(1):158.
PMID: 39103848
PARP inhibitor (PARPi) therapy has transformed outcomes for patients with homologous recombination DNA repair (HRR) deficient ovarian cancers, for example those with BRCA1 or BRCA2 gene defects. Unfortunately, PARPi resistance...
4.
Geissler F, Nesic K, Kondrashova O, Dobrovic A, Swisher E, Scott C, et al.
Ther Adv Med Oncol
. 2024 Jan;
16:17588359231220511.
PMID: 38293277
Epigenetic alterations, including aberrant DNA methylation, are now recognized as hallmarks of cancer, which can contribute to cancer initiation, progression, therapy responses and therapy resistance. Methylation of gene promoters can...
5.
Ho G, Vandenberg C, Lim R, Christie E, Garsed D, Lieschke E, et al.
Ther Adv Med Oncol
. 2023 Nov;
15:17588359231208674.
PMID: 38028140
Background: Despite initial response to platinum-based chemotherapy and PARP inhibitor therapy (PARPi), nearly all recurrent high-grade serous ovarian cancer (HGSC) will acquire lethal drug resistance; indeed, ~15% of individuals have...
6.
Cox D, Lee E, Wong B, McClure T, Zhang F, Goh S, et al.
Transplantation
. 2023 Oct;
108(4):958-962.
PMID: 37902630
Background: Ex vivo normothermic machine perfusion (NMP) is an organ preservation technique that enables an extended assessment of graft suitability before liver transplantation (LT). Established monitoring protocols used during NMP...
7.
Cox D, McClure T, Zhang F, Wong B, Testro A, Goh S, et al.
Epigenomes
. 2023 Jun;
7(2).
PMID: 37367181
: Graft-derived cell-free DNA (gdcfDNA) analysis has shown promise as a non-invasive tool for monitoring organ health following solid organ transplantation. A number of gdcfDNA analysis techniques have been described;...
8.
Joo J, Mahmood K, Walker R, Georgeson P, Candiloro I, Clendenning M, et al.
Clin Epigenetics
. 2023 Jun;
15(1):95.
PMID: 37270516
Background: MLH1 epimutation is characterised by constitutional monoallelic MLH1 promoter hypermethylation, which can cause colorectal cancer (CRC). Tumour molecular profiles of MLH1 epimutation CRCs were used to classify germline MLH1...
9.
Dall G, Vandenberg C, Nesic K, Ratnayake G, Zhu W, Vissers J, et al.
J Exp Clin Cancer Res
. 2023 May;
42(1):112.
PMID: 37143137
Background: Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA...
10.
Nesic K, Krais J, Vandenberg C, Wang Y, Patel P, Cai K, et al.
medRxiv
. 2023 Mar;
PMID: 36993400
splice isoforms Δ11 and Δ11q can contribute to PARP inhibitor (PARPi) resistance by splicing-out the mutation-containing exon, producing truncated, partially-functional proteins. However, the clinical impact and underlying drivers of exon...